Due to these potential effects of targeted therapy on the NOTCH1 signaling pathway in T-ALL but none of agents currently applied in clinical practice, we present the characterization of JX5, which could inhibit the binding of IGF2BP2 with NOTCH1 to deactivate NOTCH1 signaling in T-ALL. This evidence concerns the gene IGF2BP2 and acute lymphoblastic leukemia.